Condition: Head and Neck Squamous Cell Carcinoma HNSCC · Non-Small Cell Lung Cancer NSCLC · Esophageal Cancer · Sponsor: Sutro Biopharma, Inc.
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity. * Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.
This description comes directly from the study's public registry record.
Sutro Clinical Development · 650-801-6416 · ClinicalTrials@sutrobio.com
Always discuss trial participation with your own doctor first.
| SCRI Denver | Denver, Colorado, United States | Recruiting |
| SCRI FCS Sarasota | Sarasota, Florida, United States | Recruiting |
| Mass General Cancer Center | Boston, Massachusetts, United States | Not Yet Recruiting |
| NEXT Austin | Austin, Texas, United States | Recruiting |
| NEXT San Antonio | San Antonio, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07227168